Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for overseas listing applications for 11 companies, focusing on compliance, ownership structure, and business operations [1][2][3]. Group 1: Supplementary Material Requirements - For Avita, the requirements include clarifying the legality and fairness of past capital increases and share transfers, particularly regarding transactions at nominal or zero consideration, and the existence of shareholding proxies [1][14]. - For TuoSiDa, the focus is on the specific use of raised funds, the proportion of domestic versus overseas use, and whether necessary approvals for overseas investments have been obtained [2][5]. - For TianXiaXiu, the company must provide detailed operational information regarding its advertising and consulting services, along with legal opinions from lawyers [2][6]. - For JunSai Bio, the requirements include clarifying the actual controller's permanent residency status abroad and any historical shareholding proxies [2][9]. Group 2: Compliance and Legal Opinions - Companies are required to provide legal opinions confirming the compliance of their business operations with foreign investment regulations, particularly concerning sensitive sectors like stem cells and gene therapy [7][16]. - The CSRC emphasizes the need for companies to disclose any potential legal issues related to share pledges or freezes that may affect the listing process [10][18]. - Companies must also clarify their operational activities related to data protection and user information management, especially in the context of digital products and services [14][8]. Group 3: Ownership and Control Structure - Companies must explain discrepancies between their current and post-listing controlling shareholder structures, particularly in relation to the disclosures made in their prospectuses [2][14]. - The requirements include a thorough examination of the historical decisions made by the board and shareholder meetings to ascertain control rights [2][14]. - Companies are also asked to confirm whether their major shareholders are subject to any legal restrictions on ownership [13][17]. Group 4: Financial and Operational Transparency - Companies must detail the pricing basis for any recent share transfers and whether there are any irregularities or potential conflicts of interest [9][17]. - The CSRC requires companies to disclose their fundraising plans, including the expected amount and the implications of exercising any over-allotment options [12][18]. - Companies are also asked to provide insights into their business models, including customer and supplier relationships, and how these align with their market positioning [18].

Group 1 - The China Securities Regulatory Commission (CSRC) has disclosed requirements for supplementary materials regarding overseas issuance and listing, specifically requesting Chengyi Biotechnology to clarify compliance related to its equity structure and reverse mergers [1] - The CSRC requires the company to explain whether shareholders holding more than 5% have fulfilled foreign exchange registration and whether domestic institutional shareholders have complied with external investment regulatory procedures [1] - The CSRC also demands details on the pricing, tax payments, and compliance with regulations during the acquisition of domestic entities, particularly in the context of red-chip structure establishment [1] Group 2 - Regarding the equity situation, the CSRC has requested clarification on whether the shareholding ratio of Hangzhou AstraZeneca Zhongjin and AstraZeneca UK Limited should be consolidated and if it meets the standards for shareholders holding more than 5% [2] - The CSRC seeks detailed arrangements concerning special shareholder rights, particularly the selection rights of directors and observers, and any changes in control before and after listing [2] - The CSRC requires a conclusive opinion on whether there has been any unfair pricing for new shareholders in the past 12 months and whether there are any issues related to interest transfer in equity incentives [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for eight companies regarding their overseas issuance and listing applications, focusing on compliance, ownership structure, and potential risks associated with their operations [1][2][3]. Group 1: Supplementary Material Requirements - For Shenyan Intelligent, the company is required to explain the circumstances surrounding its previous approval for listing on the National Equities Exchange and Quotations (NEEQ) and its plans for A-share listing [1][2]. - For Haofu Creative Group, the focus is on the compliance of its equity control structure, including the acquisition processes and the reasons behind share transfers among shareholders [2][3]. - For Jinxun Co., the company must clarify whether its projects are classified as "high energy consumption" or "high emissions" and provide relevant evidence [3]. Group 2: Specific Company Requirements - For Zhejing Automotive, the company is required to provide details on its compliance with foreign investment regulations and the rationale behind recent share price variations among new shareholders [4][5]. - For Junneng Technology, the company must clarify its compliance with foreign investment regulations and provide a detailed account of its recent shareholder changes and their implications [7][8]. - For Shengtong Special Medical, the company needs to explain its business operations related to health food sales and the compliance of its equity incentive plans [14][15]. Group 3: Legal Opinions and Compliance - Companies are required to obtain legal opinions confirming the compliance of their equity structures and any potential conflicts of interest arising from recent shareholder changes [5][9][11]. - The companies must also provide evidence of their operational activities and compliance with necessary licenses, particularly in sectors that may involve foreign investment restrictions [20][21][23].

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas issuance and listing, specifically requesting information from Hantian Tiancheng regarding its previous A-share listing guidance and the reasons for termination, as well as plans for continuing A-share listing efforts [1] - Hantian Tiancheng has submitted an application for listing on the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as the sole sponsor [1] - The CSRC requires clarification on the relationship between new shareholders and the company's directors, as well as any potential conflicts of interest, and the progress of state-owned asset management procedures [1] Group 2 - Hantian Tiancheng is recognized as a leader and innovator in the global silicon carbide (SiC) epitaxy industry, being the largest supplier of SiC epitaxy by sales volume since 2023, with a market share exceeding 30% in 2024 according to a report by ZhiShi Consulting [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for overseas listing applications from several companies, focusing on compliance with tax, investment, and regulatory frameworks [1][2][4][5][8][10]. Group 1: Supplementary Material Requirements - For MicroVision Technology, the CSRC requires clarification on tax declaration and payment related to the merger with Future Vision, in accordance with relevant tax regulations [1][4]. - For Longhong New Materials, the CSRC is concerned about the legitimacy of three zero-value equity transfers in 2023 and the significant price difference in a subsequent capital increase in 2024, requiring explanations regarding the authenticity of these transactions and potential shareholding arrangements [2][10][11]. - Glen Holdings must provide details on the compliance of its equity structure and the pricing basis for a recent acquisition, ensuring adherence to foreign investment regulations [5]. - For Haichen Energy Storage, the CSRC requests information on the compliance of overseas investments, technology export activities, and data protection measures related to user information [6]. - Dongpeng Beverage is required to clarify its business scope in relation to foreign investment restrictions and provide details on user data management practices [8]. Group 2: Company-Specific Issues - MicroVision Technology must explain the compliance of its equity control structure and the operational scope of its domestic entities in the AI sector [4]. - Longhong New Materials needs to address the compliance of its equity structure and the legitimacy of its recent ownership changes, particularly regarding the zero-value transfers [2][10][11]. - Glen Holdings is tasked with detailing the compliance of its overseas subsidiaries with foreign investment regulations [5]. - Haichen Energy Storage is required to clarify its technology export activities and compliance with data protection regulations [6]. - Dongpeng Beverage must provide information on its compliance with foreign investment policies and user data management practices [8].

文/梧桐小新 4月18日，证监会公布了境外发行上市备案补充材料要求（2025年4月11日—2025年4月17日），对旷世联盟、荣联再生、博车网、微医控股、乐舒适、真实生物、群 核科技、思格新能源、中润光能这9家企业出具补充材料要求。 其中，就 旷世联盟 ，补充材料要求关注到：你公司两次申报备案报告主要变化：（1） 剥离前次备案中境内主要运营实体厦门鑫乾慧网络技术有限公司的原因及具 体情况。 （2）前次备案后，你公司新设厦门纳努克、厦门六六鳞、厦门羽钥、厦门长焱、厦门万邦、厦门因特维尔等6家境内运营实体， 目前13家境内运营实体 中仅5家实际经营业务的原因及合理性。 就 博车网 关注到：关于股权架构，请说明： （1）发行人股份回购对价、定价依据及被回购方所得税缴纳情况；（2）收购博车信息技术、恒泰博车拍卖、恒泰博 车拍卖网络、车赢信息等境内运营主体对价、对价支付、定价依据及转让方所得税缴纳情况； （3）境内企业股东所涉境外投资程序履行情况；（4）曾搭建协议架 构的原因。 就 微医控股 关注到：根据招股说明书，你公司健康管理会员服务采用按人头付费的服务模式，通过与基层医疗机构合作为会员提供服务，自当地公共医疗保险 ...